Tuesday, August 18, 2026
ExploreSearch
Finance Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Enterprise AI Agent Rollout Outpaces Data Trust and Readiness
Enterprise adoption of agentic AI is accelerating fast — Siemens deepening its NVIDIA partnership for self-verifying agentic AI in chip design, Manulife expanding its Microsoft AI-governance partnership, and a wave of infrastructure launches (NVIDIA GPU-accelerated data processing, Dell exascale storage, new AI chip generations) — even as a new Google Cloud survey shows the underlying data foundation isn't ready: companies have AI access to only 45% of their data on average, data laggards see access fall to 30% or less, and only about half of organizations trust their AI agents' decisions. Meanwhile, insider selling at enterprise-AI bellwether C3.ai (CEO Thomas Siebel offloading $4.8M in shares) hints at investor caution layered under the adoption hype.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,812
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,812 facts checked against source5,219 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 5, 2026

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

View original at finance.yahoo.com
REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 Robust patien…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • All RGX-202 pivotal dose patients exceeded expected disease trajectory on NSAA, improving average of 7.4 points vs cTAP at 18 months

    80% confidence

  • REGENXBIO is rapidly advancing late-stage pipeline with multiple near-term catalysts in 2026, driven by fully in-house capabilities, commercial-ready manufacturing, and global partners

    80% confidence

  • REGENXBIO plans to request pre-BLA meeting in mid-2026 to align with FDA on BLA submission for RGX-202

    80% confidence

  • Thousands of patients have been treated with REGENXBIO's AAV platform, including those receiving Zolgensma

    80% confidence

  • Cash balance of $240.9M as of December 31, 2025 expected to fund operations into early 2027, excluding potential partner milestone payments and non-dilutive funding

    80% confidence

  • REGENXBIO expects majority of confirmatory trial (n=30) enrolled at time of BLA submission

    80% confidence

  • Global regulatory submissions for sura-vec wet AMD are expected in 2027

    80% confidence

  • Sura-vec is potentially the first-in-class treatment for wet AMD and diabetic retinopathy

    80% confidence

  • At two years post-treatment with sura-vec Dose Level 3 in ALTITUDE trial, no intraocular inflammation was observed (n=15), 50% achieved ≥2-step DRSS improvement, and ≥70% risk reduction in vision-threatening complications vs historical controls

    80% confidence

  • REGENXBIO is working to address concerns in RGX-121 CRL with goal of resubmitting BLA

    80% confidence

  • RGX-202 is designed to be a potential best-in-class gene therapy for Duchenne with unique C-Terminal domain inclusion for muscle protection

    80% confidence

Cited in these Via News reports